DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

The S&P 500 Index ($SPX) (SPY) today is up +0.06%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.14%, and the Nasdaq ...

Regeneron Pharmaceuticals got a modest confidence bump as Mirae Asset Global ETFs Holdings added 1,712 shares to their ...

It is now illegal to publish or threaten to publish real or AI-generated intimate images of a person without their consent. Tech sites and companies also must take down such images within 48 hours of ...

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...